Strides Pharma Received Approval For Fluoxetine Tabs 60 mg From USFDA

Strides Pharma Science has announced a significant milestone with the USFDA approval of its Fluoxetine Tabs 60 mg. This achievement bolsters the company’s position in the US market, where Fluoxetine holds a substantial market share of approximately $130 million.

As a therapeutically equivalent alternative to the reference listed drug, Strides’ Fluoxetine Tabs offer a high-quality, cost-effective option for patients. The availability of three strengths – 10 mg, 20 mg, and 60 mg – in both capsule and tablet forms provides greater flexibility in dosing, catering to a wider range of patient needs.

The manufacturing of these tablets will take place at Strides’ state-of-the-art facility in Puducherry, ensuring adherence to stringent quality standards. With the imminent launch of all three strengths, Strides is poised to capitalise on the growing demand for Fluoxetine in the US market.

About Fluoxetine 

Fluoxetine is an antidepressant of the Selective Serotonin Reuptake Inhibitor (SSRI) class. It is used for the treatment of Major Depressive Disorder (MDD), Obsessive–Compulsive Disorder (OCD), Bulimia Nervosa, Panic Disorder, with or without Agoraphobia. 

About Strides Pharma Science Limited

Strides is a global pharmaceutical company headquartered in Bengaluru, India. Strides mainly operates in regulated markets, has an “in Africa for Africa” strategy, and has an institutional business to service donor-funded markets. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.